Rescuing Patient Enrollment for a Study of a Rare Mutation

A midsized pharmaceutical company was developing a treatment targeting newly diagnosed acute myeloid leukemia (AML) patients and selected Labcorp to support their global Phase III trial. Finding participants is inherently difficult with AML because most newly diagnosed patients quickly start standard treatments. In addition, many physicians are not experienced as clinical investigators for this rare disease, adding to the difficulty of rapidly identifying and enrolling potential trial volunteers

Copy and paste this URL:

https://biopharma.labcorp.com/latest-thinking/explore-library/detail.html/covance/assetLibrary/casestudies/Rescuing-Patient-Enrollment-CSCDS118.pdf